BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
This article was originally published in The Tan Sheet
Executive Summary
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary
You may also be interested in...
Bristol-Myers Squibb To Sell Australian Manufacturing Facility To Generics Maker Sigma
PERTH, Australia - Bristol-Myers Squibb revealed Sept. 7 that it plans to sell its Australian manufacturing facility in Melbourne to generic drug maker Sigma Pharmaceuticals for roughly AU$60 million. The Melbourne-based plant is the only production facility held by BMS in Australia
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb is buying the biotech company Medarex in a deal valued at $2.4 billion, or $16.00 per share in cash, the companies announced July 22. In doing so, Bristol gains full rights to the late-stage cancer drug ipilimumab and to innovative technologies for developing immunology and oncology humanized antibodies
BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says